Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	148 people with moderate to severe psoriasis	Serious adverse effects 12 weeks 4/50 (8%) with adalimumab weekly 1/45 (2%) with adalimumab every 2 weeks 0/52 (0%) with placebo	Significance not reported (P value not reported)
RCT 3-armed trial	148 people with moderate to severe psoriasis	Serious adverse effects 60 weeks with adalimumab